» Articles » PMID: 34510035

Efficacy of Sublingual Immunotherapy in Allergic Rhinitis Children During Coronavirus Disease 2019

Overview
Date 2021 Sep 12
PMID 34510035
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sublingual immunotherapy (SLIT) had good effectiveness for children with allergic rhinitis (AR). However, no studies explored the effect of persistent allergen exposure on SLIT treatment. Coronavirus disease 2019 (COVID-19) restricts outdoor activities of children significantly. We aimed to evaluate the effectiveness of SLIT during this special period.

Methods: A total of 335 AR children who sensitize to house dust mite (HDM) undergoing SLIT were recruited in this study. The clinical effectiveness and safety were evaluated at different time points using symptom and medication scores. The serum total IgE and specific IgE (sIgE) at different time points were detected by using the Unicap system.

Results: The total nasal symptoms score (TNSS) and total medication score (TMS) during the epidemic of COVID-19 increased significantly compared with the same period last year (p < 0.05), despite that they were still significantly lower than baseline levels (p < 0.05). The occurrence of adverse reactions at different time points had no significant differences. We also found that the family of the good response group had more frequent bedding cleaning. Both the tIgE and sIgE levels had no significant changes during SLIT treatment.

Conclusion: Our results suggest that continuous HDM exposure reduced the effectiveness of SLIT, whereas effective reduction of HDM levels by frequent bed cleaning will be helpful during the SLIT treatment.

Citing Articles

Efficacy of Montelukast combined with Sublingual Immunotherapy in the treatment of children with Obstructive Sleep Apnea Hypopnea Syndrome Complicated with allergic rhinitis.

Mao X, Zhao W Pak J Med Sci. 2023; 39(5):1350-1354.

PMID: 37680839 PMC: 10480714. DOI: 10.12669/pjms.39.5.6985.


Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.

Munblit D, Greenhawt M, Brough H, Pushkareva A, Karimova D, Demidova A Pediatr Allergy Immunol. 2022; 33(10):e13851.

PMID: 36282136 PMC: 9538373. DOI: 10.1111/pai.13851.